Published in World J Gastroenterol on October 28, 2014
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28
Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27
Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science (2009) 3.47
A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology (2004) 3.42
Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol (2002) 2.91
Hepatocellular carcinoma. J Hepatol (2000) 2.77
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest (2001) 2.18
Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med (2009) 1.89
Caustic injury of the upper gastrointestinal tract: a comprehensive review. World J Gastroenterol (2013) 1.86
Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol (2005) 1.79
A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology (2013) 1.72
Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol (2012) 1.70
Hepatic fibrosis. Curr Opin Gastroenterol (2009) 1.67
New concepts in liver regeneration. J Gastroenterol Hepatol (2011) 1.55
Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int (2008) 1.46
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol (2012) 1.46
Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol (2011) 1.44
Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem (2006) 1.40
Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol (2012) 1.38
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem (2002) 1.32
Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. Ann Surg (1987) 1.28
Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant (2003) 1.23
Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) (2013) 1.19
Halofuginone: a novel antifibrotic therapy. Gen Pharmacol (1998) 1.18
Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases. Cancer Lett (2003) 1.18
Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J Pathol (2013) 1.17
Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul Disord (2008) 1.15
ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. Nature (2012) 1.13
Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev (2011) 1.13
Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS One (2011) 1.12
Alcohol and pancreatic cancer. Alcohol (2005) 1.10
Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res (2006) 1.10
Chronic pancreatitis and pancreatic cancer. Dig Dis (2002) 1.08
Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol (2002) 1.08
Growth inhibition of prostate cancer xenografts by halofuginone. Prostate (2002) 1.07
Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol (1997) 1.07
New type of febrifugine analogues, bearing a quinolizidine moiety, show potent antimalarial activity against Plasmodium malaria parasite. J Med Chem (1999) 1.05
Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology (2001) 1.05
Pancreatic stellate cells: new target in the treatment of chronic pancreatitis. J Gastroenterol Hepatol (2007) 1.03
Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia (1999) 1.02
TGFbeta-induced fibrogenesis of the pancreas. Int J Gastrointest Cancer (2002) 0.99
Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions. Ann Surg (1998) 0.98
Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion. Exp Cell Res (2010) 0.98
Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol (1996) 0.97
Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol (2002) 0.97
Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer (2004) 0.97
The induction of the immediate-early-genes Egr-1, PAI-1 and PRL-1 during liver regeneration in surgical models is related to increased portal flow. J Hepatol (2002) 0.96
Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas (2009) 0.96
Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated? World J Gastroenterol (2011) 0.94
Are patients with Child's A cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation? Am J Transplant (2011) 0.93
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther (2007) 0.93
Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development. Pancreas (2010) 0.93
Risk factors for stricture development after caustic ingestion. Hepatogastroenterology (2002) 0.92
Heparanase expression during normal liver development and following partial hepatectomy. J Pathol (2004) 0.91
Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1. Egr-1 activation is an early event in liver regeneration. J Biol Chem (1999) 0.89
Prevention and management of treatment-induced pharyngo-oesophageal stricture. Lancet Oncol (2013) 0.87
Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginone. Expert Opin Drug Discov (2008) 0.87
Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia (2006) 0.87
Fibrosis of liver, pancreas and intestine: common mechanisms and clear targets? Acta Gastroenterol Belg (2001) 0.86
Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score. World J Surg (2009) 0.86
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res (2003) 0.86
Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation (1999) 0.85
Liver repopulation and regeneration: new approaches to old questions. Curr Opin Organ Transplant (2013) 0.85
Current strategies for chemoprevention of hepatocellular carcinoma. Oncology (2002) 0.85
Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol (2005) 0.85
Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model. Am J Obstet Gynecol (1999) 0.85
Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats. Lab Invest (2008) 0.84
Preventive effect of halofuginone on concanavalin A-induced liver fibrosis. PLoS One (2013) 0.84
Prevention of esophageal strictures in a caustic burn model using halofuginone, an inhibitor of collagen type I synthesis. Laryngoscope (2005) 0.83
The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of esophageal strictures related to caustic injury. Am J Surg (2004) 0.83
The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. J Urol (2000) 0.82
Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone. Cell Tissue Res (2006) 0.82
Halofuginone- and chitosan-coated amnion membranes demonstrate improved abdominal adhesion prevention. ScientificWorldJournal (2010) 0.82
Pretreatment with soluble thrombomodulin prevents intrasinusoidal coagulation and liver dysfunction following extensive hepatectomy in cirrhotic rats. Thromb Haemost (1999) 0.82
Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice. PLoS One (2012) 0.81
The chemistry and biology of febrifugine and halofuginone. Bioorg Med Chem (2014) 0.81
Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol (2002) 0.81
Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone. Histol Histopathol (2013) 0.81
Research toward safer resection of the cirrhotic liver. HPB Surg (2000) 0.81
Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem Pharmacol (2001) 0.81
The effects of methylprednisolone and halofuginone on preventing esophageal and hypopharyngeal fibrosis in delivered radiotherapy. Eur Arch Otorhinolaryngol (2010) 0.80
Role of angiotensin-1 receptor blockade in cirrhotic liver resection. Liver Int (2011) 0.79
Effect of granulocyte-macrophage colony-stimulating factor on hepatic regeneration after 70% hepatectomy in normal and cirrhotic rats. HPB (Oxford) (2002) 0.79
Preliminary results of antiscarring therapy in the prevention of postendoscopic esophageal mucosectomy strictures. Surg Endosc (2013) 0.79
Heparanase accelerates the proliferation of both hepatocytes and endothelial cells early after partial hepatectomy. Exp Mol Pathol (2012) 0.79
Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes. J Hepatol (2004) 0.78
Effects of recombinant human growth hormone on remnant liver after hepatectomy in hepatocellular carcinoma with cirrhosis. World J Gastroenterol (2004) 0.78
Halofuginone prevents subglottic stenosis in a canine model. Ann Otol Rhinol Laryngol (2006) 0.78
Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. Ann Plast Surg (2014) 0.75